Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006008 · ClinicalTrials.gov registry record · Phase 2
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 2 study of Leukemia, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00006008 is a Phase 2 study of Leukemia that has completed, run by Eastern Cooperative Oncology Group. The trial reports 20 study locations across 8 states.
The verdict
NCT00006008, a Phase 2 study of Leukemia, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory acute lymphoblastic leukemia.
Conditions Studied
Interventions
- DRUG arsenic trioxide
Study Locations (20)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- CCOP - Central Illinois - Decatur
- CCOP - Evanston - Evanston
- CCOP - Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
Florida
- Veterans Affairs Medical Center - Gainsville - Gainesville
- Veterans Affairs Medical Center - Miami - Miami
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
- Veterans Affairs Medical Center - Tampa (Haley) - Tampa
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- Veterans Affairs Medical Center - Palo Alto - Palo Alto
- Stanford University Medical Center - Stanford
Georgia
- Emory University Hospital - Atlanta - Atlanta
- Veterans Affairs Medical Center - Atlanta (Decatur) - Decatur
Indiana
- Indiana University Cancer Center - Indianapolis
- Veterans Affairs Medical Center - Indianapolis (Roudebush) - Indianapolis
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
Colorado
- CCOP - Colorado Cancer Research Program, Inc. - Denver
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006008
The ClinicalTrials.gov registry entry for NCT00006008 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00006008 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Illinois, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00006008 about?
NCT00006008 is a clinical study titled "Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory acute lymphoblastic leukemia.
What is the current status of trial NCT00006008?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06. Estimated completion is 2006-09.
What conditions does trial NCT00006008 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00006008?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00006008?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006008 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.